RNXT

RenovoRx Inc

RNXT, USA

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.

https://renovorx.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
RNXT
stock
RNXT

RenovoRx (Nasdaq: RNXT) to Present TIGeR-PaC PK/PD Data at ASCO GI Symposium 2026 Stock Titan

Read more →
RNXT
stock
RNXT

Agah Ramtin, RenovoRx chief medical officer, buys $9,600 in RNXT Investing.com

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$5.5625

Analyst Picks

Strong Buy

2

Buy

2

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

4.36

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-36.05 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-25.99 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-853.38 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.39

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 29.35% of the total shares of RenovoRx Inc

1.

AIGH Capital Management, LLC

(9.4616%)

since

2025/06/30

2.

Awm Investment Company Inc

(5.1035%)

since

2025/06/30

3.

Vanguard Group Inc

(4.5395%)

since

2025/06/30

4.

Vanguard Total Stock Mkt Idx Inv

(2.8221%)

since

2025/07/31

5.

Bleichroeder LP

(1.3644%)

since

2025/06/30

6.

Geode Capital Management, LLC

(0.9649%)

since

2025/06/30

7.

Vanguard Institutional Extnd Mkt Idx Tr

(0.8397%)

since

2025/07/31

8.

Renaissance Technologies Corp

(0.6871%)

since

2025/06/30

9.

Fidelity Extended Market Index

(0.5034%)

since

2025/07/31

10.

Vanguard Balanced Index Inv

(0.4763%)

since

2025/07/31

11.

Watch Point Trust Co

(0.2651%)

since

2025/06/30

12.

Corsair Capital Management LLC

(0.2603%)

since

2025/06/30

13.

Chicago Partners Investment Group LLC

(0.252%)

since

2025/06/30

14.

Fidelity Total Market Index

(0.2143%)

since

2025/07/31

15.

Northwestern Mutual Wealth Management Co

(0.2036%)

since

2025/06/30

16.

Charles Schwab Investment Management Inc

(0.1343%)

since

2025/06/30

17.

Schwab Total Stock Market Index

(0.1343%)

since

2025/07/31

18.

Fidelity Series Total Market Index

(0.128%)

since

2025/07/31

19.

HighTower Advisors, LLC

(0.1092%)

since

2025/06/30

20.

Kestra Advisory Services, LLC

(0.0969%)

since

2025/06/30

21.

UBS Group AG

(0.0819%)

since

2025/06/30

22.

Spartan Extended Market Index Pool F

(0.0779%)

since

2025/07/31

23.

Northern Trust Corp

(0.0731%)

since

2025/06/30

24.

State Street Corp

(0.0714%)

since

2025/06/30

25.

NT Ext Equity Mkt Idx Fd - L

(0.0708%)

since

2025/06/30

26.

Northern Trust Extended Eq Market Idx

(0.0708%)

since

2025/06/30

27.

TWO SIGMA SECURITIES, LLC

(0.0596%)

since

2025/06/30

28.

Spartan Total Market Index Pool G

(0.0592%)

since

2025/07/31

29.

HRT FINANCIAL LLC

(0.0563%)

since

2025/06/30

30.

ADAR1 Capital Management LLC

(0.0543%)

since

2025/06/30

31.

Affinity Capital Advisors, LLC

(0.0362%)

since

2025/06/30

32.

State St US Extended Mkt Indx NL Cl C

(0.0221%)

since

2025/08/31

33.

Fidelity Nasdaq Composite Index

(0.0213%)

since

2025/07/31

34.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.02%)

since

2025/06/30

35.

SSgA U.S. Total Market Index Strategy

(0.0093%)

since

2025/03/31

36.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0032%)

since

2024/12/31

37.

Northern Trust Wilshire 5000

(0.0023%)

since

2025/06/30

38.

Fidelity U.S. Equity Index Ins Trust

(0.0002%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.08

EPS Estimate

-0.08

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(3)
Quality
Low Quality Business(2.5)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.